638 results about "Parkinson's disease" patented technology

The invention relates to the field of traditional Chinese medicine, and discloses a traditional Chinese medicine composition for treating cognitive impairment of Parkinson's disease and application thereof.The traditional Chinese medicine composition is prepared from, by weight, 180-220 parts of vinegar tortoise plastron, 90-110 parts of morinda officinalis, 90-110 parts of angelica sinensis, 90-110 parts of radix curcumae, 55-65 parts of rhizoma acori graminei, 55-65 parts of polygala tenuifolia, 180-220 parts of calcined dragon bone, 180-220 parts of caulis spatholobi and 1-3 parts of borneol. When all the medicines of the traditional Chinese medicine composition are combined, the compatibility of monarch, minister, assistant and guide is performed, so that the traditional Chinese medicine composition has the effects of tonifying kidney, promoting blood circulation, dispersing blood stasis and inducing resuscitation, can relieve cognitive impairments such as space navigation, space exploration, working memory and the like of a Parkinson's disease cognitive impairment model mouse caused by chronic hypoperfusion, and realizes the treatment effect on the Parkinson's disease cognitive impairment; good application prospects are realized.

The invention relates to a Parkinson's disease treatment effect prediction method based on a multi-modal image model and a related device. The method comprises the following steps: acquiring a multi-modal vector of a Parkinson's disease patient; aligning the multi-modal vectors on a time axis, and constructing a time point data element sample sequence; deploying a double-flow cross attention encoder for a sample sequence in each time point data element, and outputting a fused multi-modal feature through the double-flow cross attention encoder; and connecting the fused multi-modal features with digital clinical treatment scheme vectors corresponding to corresponding time points to form time point comprehensive feature vectors, inputting the time point comprehensive feature vectors to a time sequence information aggregation gating circulation unit, outputting final time point aggregation features, and inputting the final time point aggregation features to a multi-task adaptive prediction head. A UPDRS total score or a specific sub-scale score for the patient at a future preset point in time is predicted. According to the method, time sequence modeling is carried out on multi-mode and multi-time-point data, so that the accuracy and interpretability of Parkinson's disease treatment effect prediction are improved.

The invention relates to a Parkinson's disease walking state recognition method based on tensor singular value decomposition and automatic hyper-parameter optimization. The Parkinson's disease walking state recognition method comprises the following steps: acquiring a sensor signal of a target person; constructing a tensor according to the sensor signal; performing t-SVD decomposition processing on the tensor to obtain a frequency domain core tensor; the frequency domain core tensor and the sensor signal are subjected to feature extraction, the extracted features are input into a trained classification model, the binary classification recognition result of the Parkinson's disease patient and the healthy person is obtained, and the trained classification model is obtained through training of a training set marked with a patient and health contrast label. According to the method, efficient dimension reduction and noise suppression are realized by using t-SVD, and adaptive optimization is performed on the key hyper-parameters of the classification model in combination with an automatic machine learning technology, so that the dichotomy recognition accuracy and robustness of the Parkinson's disease patient and the health control are improved.

The invention discloses a layering and preference learning-based personalized dynamic treatment strategy generation system for Parkinson's disease, which comprises a dynamic state and preference representation module, a preference-based reward function learning module, a layering treatment strategy generation module and a treatment path simulation and interactive output module, the system learns preferences from doctor-patient interaction and generates layered, dynamic and explainable personalized long-term treatment strategies, so that making of personalized long-term treatment decisions is achieved, and the problems that in an existing Parkinson's disease reinforcement learning scheme, an award function is fixed, and long-term planning ability is lacked are solved.

Provided are a compound having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same and a use thereof, where the compound having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof has an inhibitory activity against glucosylceramide synthase (GCS), and therefore can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.

The invention discloses an awareness perception quantum gravitational nerve acceleration unified computing platform and method based on formalized verification, and belongs to the field of high-performance computing, medical AI and quantum information processing. A quantum gravitational coupling neural processing unit (QGCNPU); a consciousness information integral calculation core (phi ICC); formalizing a receipt chain verifier (FRCV); and the mirror reflection symmetry correction module (MRSCM) is used for eliminating the continuous projection mistake and the discrete Boolean mistake through topological equivalence verification of a local observer and a global GodCam visual angle. The system adopts an FPGA + ASIC + quantum processor three-layer heterogeneous architecture, and supports real-time pathological modeling (precision gt; gt) of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and ALS; 99.7%), drug target discovery (acceleration by 50 times) and consciousness state monitoring (time resolution lt; and meanwhile, the mathematical proving performance and the clinical auditing performance of the calculation process are ensured, and the requirements of the global 152 billion dollar neural science and technology market and the 89 billion dollar quantum calculation industry are met.

A new computational approach may provide improved detection of disease conditions and comorbidities, such as PTSD, Parkinson's, Alzheimer's, depression, etc. For example, in an embodiment, a computer-implemented method for detecting a disease condition may comprise receiving a plurality of data streams, each data stream representing a measurement of a brain activity comprising physical and chemical phenomena and performing pattern analysis on the plurality of data streams to detect at least one fundamental code unit of a brain code corresponding to a disease condition based on a combination of the plurality of data streams.

The invention relates to the technical field of traditional Chinese medicines, in particular to application of a traditional Chinese medicine composition in preparation of a medicine for preventing and treating motor symptoms of Parkinson's disease. The traditional Chinese medicine composition is prepared from the following raw material medicines: 15-20 parts of rehmannia, 10-15 parts of eucommia ulmoides, 6-12 parts of gastrodia elata, 12-18 parts of concha haliotidis, 10-15 parts of parasitic loranthus, 12-18 parts of astragalus membranaceus, 6-12 parts of angelica sinensis, 5-8 parts of cassia twig and 10-15 parts of radix paeoniae alba. The composition is scientific and reasonable in component compatibility, has the effects of tonifying the kidney, calming the liver, benefiting qi, nourishing blood, regulating and tonifying the spleen and the stomach, relieving dizziness, activating blood, clearing damp and dredging collaterals, is safe to take and good in curative effect, can be effectively used for preventing and treating motor symptoms of the Parkinson's disease, and has a more remarkable treatment effect compared with other prescriptions.

A computer-implemented system, and method for classifying Parkinson's Disease (PD) from magnetic resonance imaging (MRI) data. The method includes receiving an MRI image. The method includes processing the MRI image through a C3BAM-Net convolutional neural network (CNN) architecture to obtain a plurality of attention-enhanced feature maps. The method includes classifying the input MRI image into one of a plurality of the PD categories based on the plurality of attention-enhanced feature maps. Where the C3BAM-Net CNN includes a plurality of convolutional layers, a plurality of Rectified Linear Unit (ReLU) activations, a plurality of max pooling layers, a plurality of Convolutional Block Attention Modules (CBAMs), a flattening layer, and a plurality of dense layers. The method includes each CBAM of the plurality of CBAMs includes a Channel Attention Module (CAM) and a Spatial Attention Module (SAM) arranged sequentially.

The invention belongs to the field of disease evolution trajectory prediction in precision medicine, and discloses a Parkinson's disease evolution prediction modeling method based on high-order gene communication tensor. According to the method, firstly, based on an intercellular communication mechanism, a high-order gene module communication tensor is constructed as spatial topological data, so that an information interaction mode between gene modules is described; secondly, a self-adaptive Transform module is designed to extract gene expression features and high-order space topology features at the same time; and finally, integrating multi-view interaction information between the high-order gene module communication tensor and the whole blood transcriptome data through a multi-view collaborative fusion mechanism to realize effective fusion and utilization of features. Experimental results show that compared with a traditional genetic map, the high-order space representation provided by the invention has finer resolution capability, a plurality of evaluation indexes are remarkably improved, and a new technical means is provided for accurate staging of Parkinson's disease.

The invention relates to the technical field of medical image processing, provides a Parkinson's disease early diagnosis method based on gait image analysis, and aims to solve the problem of accurate diagnosis of Parkinson's disease under complex terrains. According to the method, a three-dimensional point cloud image sequence and six-axis motion sensor data are synchronously collected through an RGB-D camera and an inertial measurement unit, a dynamic topological graph is generated, topographic change features are extracted, and gait anomaly features are separated by using a multi-scale convolutional neural network and a graph attention network. Multi-modal fusion is carried out to calculate plantar pressure and a joint movement compensation matrix, and a pre-training diagnosis model is input to output a Parkinson's disease diagnosis result and a Hoehn-Yahr staging grade, so that the early diagnosis accuracy is improved.

The invention belongs to the technical field of medicine synthesis, and particularly relates to a memantine derivative and a synthesis method and application thereof. The memantine derivative comprises an intermediate structural formula I, an intermediate structural formula II, an intermediate structural formula III and a structural general formula, Linker is substituted or unsubstituted C6-C10 aroyl, R1 is hydrogen or C1-C6 alkyl, R2 is hydrogen, C1-C6 alkyl or a nitrogen-containing or nitrogen-free structural fragment, or the integral structure of R1 and R2 is N-substituted heterocyclic pentyl or heterocyclic cyclohexyl. According to the memantine derivative provided by the invention, a memantine group is combined with an OAB-14 partial structure to change a parent nucleus structure, so that the drug activity is improved. The invention also provides a synthesis method of the compound, and the obtained compound is used for treating Alzheimer's disease and Parkinson's disease.

The invention relates to a disease-specific quantitative trait locus identification method based on multi-omics integration. The method comprises the following steps: acquiring variation sites of whole genome sequencing data of a target object, and molecular phenotypes and molecular abundance of molecular phenotype data; determining an association significance probability value of an association pair formed by the variation point and the molecular phenotype based on the variation point and the molecular abundance, and screening a first association pair from the association pair based on the association significance probability value and condition analysis; determining a consistent second association pair in the normal association pair and the disease association pair, and determining a third association pair with a disease interaction effect in the second association pair; calculating a first effect estimation value and a second effect estimation value of each third association pair; and based on the first effect estimation value and the second effect estimation value of the third correlation pair, determining a target correlation pair related to the Parkinson's disease, and taking the target correlation pair as the identified quantitative trait site. By adopting the method, the Parkinson's specific pathogenic heritable variation can be accurately identified.

The present invention relates to a compound of formula (I) wherein R1 is a hydrogen atom, halogen or -(C1-C2)alkyl, R2 is -halo(C1-C2)alkoxy, and R3 and R4 form together with N to which they are attached an optionally substituted 5-7 membered monocyclic heterocycloalkyl ring or an optionally substituted 8-11 membered bicyclic heterocycloalkyl ring. The present invention also relates to a medicament and a pharmaceutical composition comprising said compound of formula (I), as well as their therapeutic uses, in particular as inhibitor of NOD-like receptor protein 3 inflammasome for preventing and / or treating Parkinson's disease, frontotemporal Dementia, Multiple System Atrophy, Alzheimer's disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis or brain injury.

The present invention relates to a system and method configured for analysing acoustic parameters of speech to detect, diagnose, predict and / or monitor progression of a condition, disorder, or disease, and more particularly, any of paediatric and adult neurological and central nervous system conditions including but not limited to low back pain, multiple sclerosis, stroke, seizures, Alzheimer's disease, Parkinson's disease, dementia, motor neuron disease, muscular atrophy, acquired brain injury, cancers involving neurological deficits, paediatric developmental conditions and rare genetic disorders such as spinal muscular atrophy. The system and method extracts a first formant data set from words spoken by an individual and uses these to classify the vowels in the words on a first computing device, such as a mobile smart phone equipped with a microphone into which an individual speaks. The system stores at least some of these frequencies for the vowel formants in a second formant data set as a recorded file and provides the second formant data set as input to acoustic metrics to generate score data from which an assessment is made to determine the articulation level of the vowels in the words spoken by the individual, allowing allow for detection, diagnosis, prediction and / or monitoring progression of the condition, disorder, or disease.

Novel and known substituted purine compounds and salts thereof act as adenosine A2a receptor (A2aR) antagonists for cancer immunotherapy, depression, anxiety, multiple sclerosis, NASH, scleroderma, ADHD, Alzheimer's and Parkinsons. Pharmaceutical compositions comprising such compounds, and methods of their use in treating depression are also taught.

The application relates to fused pyrimidinone derivatives of the general formula (I) which act as agonists of Triggering Receptor Expressed on Myeloid cells 2 (TREM2) useful for the treatment of Parkinson's disease, rheumatoid arthritis, Alzheimer's disease, amyotrophic lateral sclerosis, Nasu-Hakola disease, frontotemporal dementia, multiple sclerosis, prion disease, and stroke.

The present invention relates to anti-CD 103 antibodies, as well as use of these antibodies in diagnosis, prognosis, monitoring, and treatment of diseases. Also disclosed is an imaging agent comprising the anti-CD 103 antibody and a detectable label, wherein the antibody either does not block CD 103 binding to E-cadherin or at least partially blocks CD 103 binding to E-cadherin. The methods of treatment involve administering the anti CD 103 antibody which may be optionally coupled to a cytotoxic agent. Diseases to be treated include e.g. Hairy Cell leukemia, HCLv, intestinal and extraintestinal lymphomas, enteropathy-associated T-cell lymphoma (EATL), T-lymphoblastic leukemia / lymphoma (T-ALL), T-cell prolymphocytic leukemia (T-PLL), adult T cell leukemia / lymphoma (ATLL), mycosis fungoides (ME), anaplastic large cell lymphoma ALCL, cutaneous T-cell lymphoma (CTCL), Sezary Syndrome (SS), Alzheimer's disease, Parkinson's disease or multiple sclerosis.

The utility model discloses a handheld stabilizing device for a Parkinson's disease patient. The handheld stabilizing device comprises a handle, a shell, a buffering piece, an adjusting mechanism, buffering rubber, a clamping mechanism and accessories. The front end of the handle is in threaded connection with the hollow shell, the buffering piece is movably connected in the shell, the adjusting mechanism is arranged at the front end of the buffering piece, the clamping mechanism is arranged at the tail end of the buffering piece, and the buffering rubber is arranged in the center of the buffering piece to connect the clamping mechanism and the adjusting mechanism. The adjusting mechanism comprises a knob, a sliding block, a square block, a cylinder and a spring; the sliding block is a triangular block, a square block is arranged at the bottom of the sliding block, a cylinder is arranged on the other side of the sliding block, and a hexagonal groove is formed in the front end face of the buffering piece and movably connected with the sliding block. Six sliding grooves are formed in the knob and movably connected with a sliding block through a cylinder, and a groove is formed in the cylinder at the rear end of the sliding block and movably connected with a spring.

The present invention provides compounds of formula (I) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.Accordingly, the present invention relates to compounds of formula (Id)whereinR1 is H and R2 is selected from one of the substituents (i) and (ii) below; orR1 is selected from one of the substituents (i) and (ii) below and R2 is H; orR1 and R2 are both represented by substituent (i) below; orR1 and R2 are both represented by substituent (ii) below; orR1 is substituent (i) and R2 is substituent (ii); orR1 is substituent (ii) and R2 is substituent (i);wherein * indicates the attachment point; andwherein the carbon atom at the attachment point on substituent (i) is in the S-configuration;or a pharmaceutically acceptable salt thereof.

Alkoxy-substituted N-benzyl-2-phenylacetamide compounds and derivatives are G-protein coupled receptor (GPR) 88 modulators for use in the treatment of a disease mediated by GPR88. Indications include Tourette's Syndrome, Huntington's Disease (HD), Addiction, Parkinson's Disease (PD), Schizophrenia, and Attention Deficit Hyperactivity Disorder (ADHD), choreiform movements, speech delay, learning disabilities, depression, hyperkinetic movement disorders characterised by chorea and / or dystonia, psychosis, cognitive deficits in schizophrenia, affective disorders, bipolar disorder, Alzheimer's disease and basal ganglia disorders.

The application discloses a fiber bundle automatic segmentation and quantitative labeling method for white matter abnormalities of Parkinson's disease, and belongs to the technical field of medical image processing. The application solves the problem that the existing technology relies on manual delineation or traditional machine learning methods for white matter abnormality detection, and has the problems of low efficiency and strong subjectivity. By setting a first threshold value and a second threshold value, not only can the abnormal fiber bundle be identified, but also the required threshold range can be selected according to different research purposes and clinical needs, so that reliable judgment results can be provided in both diagnosis and early screening. If both threshold values are selected, the method can comprehensively judge each parameter of each fiber bundle, so as to more accurately identify the white matter abnormal fiber bundle of the Parkinson's disease patient, improve the accuracy of the fiber bundle labeling result of the white matter abnormalities of Parkinson's disease, realize the function of high-precision positioning of the white matter abnormal fiber bundle of Parkinson's disease, and provide stronger support for clinical diagnosis.

The application discloses a Parkinson gait evaluation method and system based on a millimeter wave radar signal. The method comprises the following steps: acquiring a millimeter wave radio frequency signal in an environment, performing data processing on the signal to obtain a distance spectrum of position change of a Parkinson patient's body and a Doppler spectrum reflecting the degree of change of the Parkinson patient's body; extracting a peak value at each moment from the distance spectrum through a filtering method, calculating a cross-correlation coefficient of the Doppler spectrum as an index of gait pattern matching, and dividing the Doppler spectrum according to each step; calculating gait features according to the filtered distance spectrum peak value and the divided Doppler spectrum; inputting the normalized gait features into a trained machine learning model for feature evaluation to obtain a UPDRS-III score of the patient. The application realizes non-invasive measurement and evaluation of Parkinson gait features in a low-cost manner, is convenient to operate, and is accurate in evaluation effect, thereby providing quantitative data and diagnosis reference for doctors.

The invention belongs to the technical field of traditional Chinese medicine compound preparations, and particularly relates to a qi-regulating, phlegm-reducing and nerve-calming paste, a preparation method thereof and application of the paste in preparation of a medicine for treating Parkinson's disease combined with rapid eye movement sleep behavior disorder. The paste is prepared from the following raw materials in parts by weight: 9-30 parts of semen ziziphi spinosae, 15-30 parts of Chinese yam, 10-15 parts of poria with hostwood, 9-30 parts of semen coicis, 3-10 parts of pericarpium citri reticulatae, 3-10 parts of fingered citron, 10-20 parts of sesame, 10-20 parts of rock candy and 3-5 parts of maltose. By nourishing the heart and strengthening the spleen to consolidate the root, regulating qi and reducing phlegm to relieve stagnation and tranquilizing and sedating the physique to return to the soul, the three methods are combined to achieve the purposes of tonifying without stagnation, eliminating without injury, recovering the heart and the spleen, smoothing phlegm and qi and self-hiding the soul.

The present invention provides sulfamate derivative prodrugs of the dopamine agonist (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol, their use in treating conditions for which treatment with a dopamine agonist has therapeutic benefit, and pharmaceutical compositions comprising a compound of the present invention. The compounds according to the present invention have the formula (Id), wherein R1and R2are each independently selected from H and the substituent (iii) below, wherein * indicates the point of attachment to oxygen, wherein R3is selected from H and COR4, and wherein R4is selected from H and C1-C6alkyl, with the proviso that R1and R2cannot both be H, 15or a pharmaceutically acceptable salt thereof.

Disclosed are pharmaceutical compositions comprising azelastine or a pharmaceutically acceptable salt of azelastine and methylcobalamin. Also disclosed are methods of using the pharmaceutical compositions to treat patients suffering from Alzheimer's disease or Parkinson's disease.

The invention provides application of dynamic cortex inhibition imbalance in clinical progress prediction of early Parkinson's disease. The key function of bilateral cortex inhibition balance in adjusting the motion compensation ability of the Parkinson's disease in the early stage is clarified. By analyzing the change of the two inhibition pathways, the change of delta SICI ' / LICI' is found to be a sensitive index capable of predicting the disease progress of the patient with the early Parkinson's disease. ROC results show that the delta SICI ' / LICI' has very high discrimination capability in the aspect of predicting disease progression, the area under curve (AUC) is 0.841, the sensitivity is 87.5%, the specificity is 72.73%, and the Eyden index is 0.602. The research of the invention makes deeper understanding of the pathophysiological mechanism of Parkinson's disease, and highlights the importance of cortex inhibition balance in disease evolution. These observations also support the development of more targeted therapeutic interventions to alleviate symptom progression.

The invention discloses a tomography and targeted energy thermal therapy system and method based on an acousto-optic coupling functional film layer, and relates to the technical field of noninvasive medical diagnosis and treatment. The system comprises an intelligent processing carrier, an acousto-optic coupling function film layer, a scanning mechanism, an energy treatment module and a processing and temperature control module. The intelligent processing carrier at least comprises a 20Hz-20kHz audio unit, a pickup unit, an optical signal unit and a processor; the acousto-optic coupling functional film layer is of a single physical structure and is inseparable, acoustic frequency conversion focusing imaging and targeted warm delivery at 42-47 DEG C are achieved in the same physical area in a time-sharing mode, the acoustic processing layer achieves 1000-8000 frequency doubling through a multi-stage resonance microcavity array, and the echo signal-to-noise ratio is larger than or equal to 15 dB; the scanning mechanism comprises a plurality of modes such as rotation, translation, multi-device array, human body movement, local limb movement, human body bearing support device movement and the like; the energy forms cover all types of light, electromagnetism, radio frequency and the like capable of generating a warm effect, including but not limited to non-contact or contact energy delivery modes. The traditional Chinese medicine composition is suitable for tumors, infections, inflammations, and all lesions sensitive to temperature of 42-47 DEG C including nervous system lesions such as amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, multiple sclerosis and the like, is low in cost, free of radiation and easy to popularize, and has extremely high creativity and practical value.

The invention belongs to the field of pathologies affecting the central nervous system: in particular, severe cerebral pathologies, more particularly those restricted by the presence of the blood-brain barrier (BBB): gliomas, cerebral metastases, neurodegenerative diseases (e.g. Alzheimer's, Parkinson's or ALS), genetic diseases (Huntington's, myopathies, Leigh syndrome, Rett syndrome), but also to the field of cancers, musculoskeletal and immunological disorders, vascular diseases (thrombus) in numerous organs (e.g. liver, kidney or muscle) and in combination with numerous therapeutic approaches (e.g. chemotherapy, immunotherapy, targeted therapy or gene therapy). The invention relates to a microbubble comprising a fluorinated polymer or copolymer and a fluorinated gas, to the use thereof and also to the polymer or copolymer intermediate compounds.

The present invention relates to the use of antimiR-27b compounds for treatment or alleviation of Parkinsons Disease. The compounds of the invention have been found to be capable of preventing dopaminergic neuronal degradation in PD models, as well as influencing important pathways relevant for development of Parkinsons Disease.